32363-23-8

Upstream product

• 1193-47-1 2,2-dimethyl-cyclohexanone 
• 145100-51-2 N-(5-chloropyridin-2-yl)-1,1,1-trifluoro-N-[(trifluoromethyl)sulphonyl]methanesulphonamide 
• 37595-74-7 N,N-phenylbistrifluoromethane-sulfonimide 

Downstream Products

• 105593-28-0 β-ionone 
• 1393654-57-3 3-(3-(6,6-dimethylcyclohex-1-en-1-yl)propyl)-2H-chromen-2-one 
• 1142226-06-9 (2-(2,2-dimethylcyclohexyl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-4-yl)methanol 
• 1142234-82-9 (2-((1R)-2,2-dimethylcyclohexyl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-4-yl)methanol 
• 1142234-83-0 (2-((1S)-2,2-dimethylcyclohexyl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-4-yl)methanol 
• 1142226-00-3 (2-(6,6-dimethyl-1-cyclohexen-1-yl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-4-yl)methanol 
• 1254470-32-0 1,2,3,4-tetrahydro-2-(3-(6,6-dimethylcyclohex-1-enyl)-1-phenylprop-2-ynyl)isoquinoline 
• 1142225-97-5 2-(6,6-dimethyl-1-cyclohexen-1-yI)-4,4,5,5-tetramethyI-1,3,2-dioxaborolane 
• 309718-50-1 tert-butyl 2-[(6,6-dimethylcyclohex-1-enyl)carbonyl]indole-1-carboxylate 

Relevant academic research and scientific papers

Catalytic allylic oxidation to generate vinylogous acyl sulfonates from vinyl sulfonates

Regioselective formation of vinylogous acyl sulfonates was accomplished via the allylic oxidation of the corresponding vinyl sulfonates. The reaction progressed through the agency of catalytic iron(III) chloride catalysis with tert-Butyl hydroperoxide (TBHP) as the stoichiometric oxidant. Tolerance of other functional groups, including some other allylic and benzylic sites, was observed.

Generation of cycloalkynes through deprotonation of cyclic enol triflates with magnesium bisamides

Deprotonative generation of cyclohexynes, cycloheptynes, and cyclooctynes was achieved by controlling the reactivities of transient anionic species from the corresponding enol triflates with magnesium bis(2,2,6,6-tetramethylpiperidide) as a base. The star

INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES

The present invention relates to compounds of formula (1) as claimed in claim 1, their use in the treatment or the prevention of viral disorders, including HIV. (Formula I)

INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds defined by formula (I) wherein the variables R1, R2, R3, m, and n are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are activato

INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds defined by formula (I) wherein the variables R1, R2, R3, m, and n are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are activators of the receptor GPR40 and thus are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

SPIROCYCLIC GPR40 MODULATORS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I'A or I'B, where the definitions of the variables are provided herein. The present invention also

CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.